Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001477932-25-003069
Filing Date
2025-04-29
Accepted
2025-04-29 16:18:50
Documents
13
Period of Report
2025-04-24

Document Format Files

Seq Description Document Type Size
1 DEF 14A vnrx_def14a.htm DEF 14A 652091
2 vnrx_def14aimg9.jpg GRAPHIC 21013
3 vnrx_def14aimg24.jpg GRAPHIC 40630
4 vnrx_def14aimg23.jpg GRAPHIC 5107
5 vnrx_def14aimg21.jpg GRAPHIC 4860
6 vnrx_def14aimg20.jpg GRAPHIC 126090
7 vnrx_def14aimg19.jpg GRAPHIC 173243
8 vnrx_def14aimg18.jpg GRAPHIC 203945
9 vnrx_def14aimg17.jpg GRAPHIC 151333
10 vnrx_def14aimg15.jpg GRAPHIC 44272
11 vnrx_def14aimg14.jpg GRAPHIC 3706
12 vnrx_def14aimg13.jpg GRAPHIC 4196
13 vnrx_def14aimg11.jpg GRAPHIC 4268
  Complete submission text file 0001477932-25-003069.txt   1732528
Mailing Address 1489 WEST WARM SPRINGS ROAD SUITE 110 HENDERSON NV 89014
Business Address 1489 WEST WARM SPRINGS ROAD SUITE 110 HENDERSON NV 89014 1 (646) 650-1351
VOLITIONRX LTD (Filer) CIK: 0000093314 (see all company filings)

EIN.: 911949078 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-36833 | Film No.: 25887918
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)